CD274 and neoplasm: Understanding the mechanisms that underlie PD-L1 expression in the oncology perspective will help in developing novel strategies to improve outcomes on ICIs, by either delaying or overcoming the onset of resistance to this class of drugs through increasing or re-enabling PD-L1 expression on tumor cells or preventing PD-L1 downregulation.